These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21983935

  • 1. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
    [Abstract] [Full Text] [Related]

  • 2. ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O.
    Histopathology; 2012 Jun; 60(7):1073-83. PubMed ID: 22348389
    [Abstract] [Full Text] [Related]

  • 3. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
    Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
    [Abstract] [Full Text] [Related]

  • 4. Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.
    Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.
    Virchows Arch; 2009 Nov; 455(5):413-22. PubMed ID: 19855998
    [Abstract] [Full Text] [Related]

  • 5. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 6. Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
    Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O.
    Mod Pathol; 2008 Feb; 21(2):115-24. PubMed ID: 18084257
    [Abstract] [Full Text] [Related]

  • 7. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY, Shim SH, Jung HY, Dong M, Kim SN, Lee SJ.
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [Abstract] [Full Text] [Related]

  • 8. Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.
    Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O.
    J Pathol; 2008 Sep; 216(1):103-10. PubMed ID: 18600856
    [Abstract] [Full Text] [Related]

  • 9. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
    Xiao W, Awadallah A, Xin W.
    Int J Clin Exp Pathol; 2012 Sep; 5(7):642-50. PubMed ID: 22977660
    [Abstract] [Full Text] [Related]

  • 10. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 11. Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma.
    Kato M, Yamamoto S, Takano M, Matsubara O, Furuya K.
    Int J Gynecol Pathol; 2012 May; 31(3):254-63. PubMed ID: 22498943
    [Abstract] [Full Text] [Related]

  • 12. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.
    Yamashita Y, Akatsuka S, Shinjo K, Yatabe Y, Kobayashi H, Seko H, Kajiyama H, Kikkawa F, Takahashi T, Toyokuni S.
    PLoS One; 2013 May; 8(3):e57724. PubMed ID: 23469222
    [Abstract] [Full Text] [Related]

  • 13. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.
    Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K, Tamai S, Matsubara O.
    Am J Surg Pathol; 2007 Jul; 31(7):999-1006. PubMed ID: 17592265
    [Abstract] [Full Text] [Related]

  • 14. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
    Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O.
    J Pathol; 2011 Oct; 225(2):189-94. PubMed ID: 21735444
    [Abstract] [Full Text] [Related]

  • 15. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.
    Yamamoto S, Tsuda H, Suzuki K, Takano M, Tamai S, Matsubara O.
    Virchows Arch; 2009 Sep; 455(3):261-70. PubMed ID: 19655165
    [Abstract] [Full Text] [Related]

  • 16. [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].
    Staebler A.
    Pathologe; 2011 Nov; 32 Suppl 2():265-70. PubMed ID: 21809064
    [Abstract] [Full Text] [Related]

  • 17. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.
    Wei JJ, William J, Bulun S.
    Int J Gynecol Pathol; 2011 Nov; 30(6):553-68. PubMed ID: 21979592
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.
    BMC Cancer; 2014 Nov 03; 14():799. PubMed ID: 25366985
    [Abstract] [Full Text] [Related]

  • 19. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma.
    Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M, Tachikawa T.
    Med Electron Microsc; 2004 Sep 03; 37(3):188-92. PubMed ID: 15449112
    [Abstract] [Full Text] [Related]

  • 20. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
    Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P.
    Mod Pathol; 2012 Jun 03; 25(6):885-92. PubMed ID: 22301703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.